focus -WSS

focus

author：focus 2025-09-06 02:12:57 - browse：7399

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Sickle cell gene therapy cures need to be accessible in Africa

focus

WSS

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

First Opinion on colorectal cancer screening: letter and response

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

The debate over Covid

Harvard scientists, with Google, unveil the most detailed brain map ever

Alzheimer's risk factor APOE4 may be a distinct form of the disease

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Study: Black kids more likely to die after surgery than white kids

Medicare details structure of new drug price negotiation program

Young boy dies in trial for Pfizer Duchenne gene therapy

Psychedelics group wrestles with new pharma identity

Pancreatic cancer is often deadly, but new discoveries are raising hope

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Overprescribed: High cost isn't America's only drug problem

Walensky prepares to leave CDC — and Congress — behind

Sickle cell gene therapy cures need to be accessible in Africa

hotspot

Antibody drugs appear effective. Now can we make enough of them?

Young boy dies in trial for Pfizer Duchenne gene therapy

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Digital health funding stays low as a new reality sets in

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

hotspot

focus

hotspot

knowledge